Related references
Note: Only part of the references are listed.A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation
N. Shuker et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time
Carin A. T. C. Lunenburg et al.
EUROPEAN JOURNAL OF CANCER (2016)
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients-A Prospective, Randomized Study
Elisabet Storset et al.
TRANSPLANTATION (2015)
Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies
L. Rojas et al.
PHARMACOGENOMICS JOURNAL (2015)
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks
Laure Elens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients
Julie Bloch et al.
PHARMACOGENOMICS (2014)
Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical Trials
R. Bouamar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Tacrolimus-induced nephrotoxicity and genetic variability: A review
Saskia N. de Wildt
Annals of Transplantation (2013)
Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure
Jason Moore et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Pharmacogenetics in Kidney Transplantation Recent Updates and Potential Clinical Applications
Laure Elens et al.
MOLECULAR DIAGNOSIS & THERAPY (2012)
The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis
Salvatore Terrazzino et al.
PHARMACOGENETICS AND GENOMICS (2012)
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
Laure Elens et al.
CLINICAL CHEMISTRY (2011)
Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference
Pierre Wallemacq et al.
THERAPEUTIC DRUG MONITORING (2009)
The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study
Henrik Ekberg et al.
TRANSPLANTATION (2009)
Reduced exposure to calcineurin inhibitors in renal transplantation
Henrik Ekberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation
IAM MacPhee et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
E Thervet et al.
TRANSPLANTATION (2003)
Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study
R Margreiter
LANCET (2002)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Share Paper
